Multiple kinases including GSK3β, LRRK2 and CK1δ, among others, are involved in this pathological aggregation.[11, 12] Currently, different BACE1 and protein kinase inhibitors have reached clinical trials but none has been approved by the regulatory agencies so far.[13, 14] Our goal is to design multitarget compounds able to interfere simultaneously with three different targets involved in AD: BACE1 and, at least, two different protein kinases. Here, BACE1 is linked to Alzheimer disease.